UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results